

Eli Lilly to expand its diabetes portfolio

21 July 2014 | News | By BioSpectrum Bureau

Eli Lilly expanding diabetes portfolio in India



With an aim to enhance its diabetes treatment portfolio in one of Asia's top markets, US based pharma major Eli Lilly is planning to launch a new product.

To be launched by the end of next year, the company is now awaiting regulatory approval for the new product.

Mr Edgard A Olaizola, managing director, Eli Lilly and Company India said in a media statement, "We expect to launch a new product in the diabetes segment in India by the end of 2015. It has been submitted for regulatory approval."

He added that diabetes is a core segment for the company in India. "Early in the year, we had introduced Savvio, an insulin delivery device in India. The launch of Savvio marked an important milestone for the company," Mr Olaizola pointed out.

The company also said that in January this year they launched Humapen Savvio, its original research product in India. "It is a very important market for the company in Asia specially in diabetes. Though the biggest markets for the company globally are the US, Europe and Japan," he said.

Currently, the Indian wing of the US based company has products available to treat diabetes, cancer, cardiovascular

diseases, osteoporosis and growth disorders in the country.

Commenting on the expected growth in the Indian sub-continent, Mr Olaizola said, "We are very happy with the performance we have made in India in the last two to three years, especially in diabetes. Our vision is to be a powerhouse in diabetes."